NASDAQ:IRIX IRIDEX (IRIX) Stock Price, News & Analysis $0.88 +0.00 (+0.22%) As of 03:59 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About IRIDEX Stock (NASDAQ:IRIX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get IRIDEX alerts:Sign Up Key Stats Today's Range$0.88▼$0.9150-Day Range$0.88▼$1.3052-Week Range$0.78▼$2.41Volume83,911 shsAverage Volume51,900 shsMarket Capitalization$14.81 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewIRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.Read More… IRIDEX Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks14th Percentile Overall ScoreIRIX MarketRank™: IRIDEX scored higher than 14% of companies evaluated by MarketBeat, and ranked 616th out of 665 stocks in the computer and technology sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for IRIDEX. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of IRIDEX is -2.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of IRIDEX is -2.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIRIDEX has a P/B Ratio of 6.78. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about IRIDEX's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.78% of the float of IRIDEX has been sold short.Short Interest Ratio / Days to CoverIRIDEX has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in IRIDEX has recently decreased by 7.89%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIRIDEX does not currently pay a dividend.Dividend GrowthIRIDEX does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.78% of the float of IRIDEX has been sold short.Short Interest Ratio / Days to CoverIRIDEX has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in IRIDEX has recently decreased by 7.89%, indicating that investor sentiment is improving significantly. News and Social Media1.9 / 5News Sentiment0.39 News SentimentIRIDEX has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.81 average news sentiment score of Computer and Technology companies.News Coverage This WeekMarketBeat has tracked 3 news articles for IRIDEX this week, compared to 1 article on an average week. Company Ownership1.7 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, IRIDEX insiders have bought more of their company's stock than they have sold. Specifically, they have bought $51,657.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 7.40% of the stock of IRIDEX is held by insiders.Percentage Held by InstitutionsOnly 20.10% of the stock of IRIDEX is held by institutions.Read more about IRIDEX's insider trading history. Receive IRIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IRIDEX and its competitors with MarketBeat's FREE daily newsletter. Email Address IRIX Stock News HeadlinesIRIDEX (NASDAQ:IRIX) and Infinite Group (OTCMKTS:IMCI) Critical ReviewJune 29 at 4:11 AM | americanbankingnews.comIridex Announces First Patient Enrolled in an Independent Landmark Investigator-Led UK Study Evaluating MicroPulse® Technology as an Adjunct to anti-VEGF Therapy for Diabetic Macular EdemaJune 24, 2025 | globenewswire.comA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. June 30 at 2:00 AM | Porter & Company (Ad)IRIDEX expands stock plan and amends charterJune 15, 2025 | investing.comIRIDEX Stock Price HistoryJune 2, 2025 | investing.comThursday’s Insider Activity: Top Buys and Sells in US StocksMay 30, 2025 | investing.comIRIDEX Faces Nasdaq Delisting Over Equity ShortfallMay 21, 2025 | investing.comIRIDEX Corporation (NASDAQ:IRIX) Q1 2025 Earnings Call TranscriptMay 16, 2025 | insidermonkey.comSee More Headlines IRIX Stock Analysis - Frequently Asked Questions How have IRIX shares performed this year? IRIDEX's stock was trading at $1.68 at the beginning of the year. Since then, IRIX shares have decreased by 47.5% and is now trading at $0.8819. View the best growth stocks for 2025 here. How were IRIDEX's earnings last quarter? IRIDEX Corporation (NASDAQ:IRIX) announced its earnings results on Tuesday, May, 13th. The medical equipment provider reported ($0.10) earnings per share for the quarter, meeting the consensus estimate of ($0.10). The medical equipment provider earned $11.90 million during the quarter, compared to analysts' expectations of $12.10 million. IRIDEX had a negative trailing twelve-month return on equity of 290.57% and a negative net margin of 14.61%. Read the conference call transcript. How do I buy shares of IRIDEX? Shares of IRIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of IRIDEX own? Based on aggregate information from My MarketBeat watchlists, some other companies that IRIDEX investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Broadcom (AVGO), Meta Platforms (META), CymaBay Therapeutics (CBAY), Arista Networks (ANET) and CrowdStrike (CRWD). Company Calendar Last Earnings5/13/2025Today6/30/2025Next Earnings (Estimated)8/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorComputer and Technology Industry LASERS - SYS/COMP Sub-IndustryMedical Equipment Current SymbolNASDAQ:IRIX CIK1006045 Webwww.iridex.com Phone(650) 940-4700Fax650-940-4710Employees120Year Founded1989Profitability EPS (Most Recent Fiscal Year)($0.43) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$8.91 million Net Margins-14.61% Pretax Margin-14.53% Return on Equity-290.57% Return on Assets-22.86% Debt Debt-to-Equity Ratio4.28 Current Ratio1.95 Quick Ratio1.27 Sales & Book Value Annual Sales$48.67 million Price / Sales0.30 Cash FlowN/A Price / Cash FlowN/A Book Value$0.13 per share Price / Book6.78Miscellaneous Outstanding Shares16,790,000Free Float15,547,000Market Cap$14.79 million OptionableOptionable Beta0.62 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:IRIX) was last updated on 6/30/2025 by MarketBeat.com Staff From Our PartnersAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredGold Shock (insane new prediction)World Gold Council reports: "No sign" of this catalyst slowing A whopping 73% of Americans report they're "...Stansberry Research | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredWhy Is President Trump Fast-Tracking These Companies?Forget about AI… There's a hot new trend on Wall Street… And it's all thanks to President Trump. His ...InvestorPlace | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IRIDEX Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share IRIDEX With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.